---
title: How we reduce and treat post-transplant relapse of MDS
date: '2024-02-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38306658/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240203170617&v=2.18.0
source: Blood
description: Allogeneic hematopoietic stem cell transplant (HSCT) is the only potentially
  curative option for patients with high-risk myelodysplastic syndromes (MDS). Advances
  in conditioning regimens and supportive measures have reduced treatment-related
  mortality and increased the role of transplantation, leading to more patients undergoing
  HSCT. However, post-transplant relapse of MDS remains a leading cause of morbidity
  and mortality for this procedure necessitating expert management and ongoing ...
disable_comments: true
---
Allogeneic hematopoietic stem cell transplant (HSCT) is the only potentially curative option for patients with high-risk myelodysplastic syndromes (MDS). Advances in conditioning regimens and supportive measures have reduced treatment-related mortality and increased the role of transplantation, leading to more patients undergoing HSCT. However, post-transplant relapse of MDS remains a leading cause of morbidity and mortality for this procedure necessitating expert management and ongoing ...